Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 6.000-6.400 for the period, compared to the consensus estimate of 5.970. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $71.69 on Friday. The firm has a market capitalization of $8.39 billion, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 0.41 and a beta of 1.16. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The firm’s fifty day moving average price is $70.23 and its two-hundred day moving average price is $61.92. Halozyme Therapeutics has a 1 year low of $42.01 and a 1 year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter last year, the firm posted $0.91 EPS. The company’s quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HALO. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. Finally, JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $70.44.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $74.44, for a total value of $1,488,800.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $54,618,042.36. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the transaction, the director directly owned 44,952 shares in the company, valued at approximately $3,382,188.48. This represents a 4.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,227 shares of company stock valued at $6,020,595. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares in the last quarter. AXA S.A. boosted its stake in shares of Halozyme Therapeutics by 0.4% in the 2nd quarter. AXA S.A. now owns 123,012 shares of the biopharmaceutical company’s stock valued at $6,399,000 after purchasing an additional 512 shares in the last quarter. Baird Financial Group Inc. boosted its stake in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares in the last quarter. Diversify Advisory Services LLC boosted its stake in shares of Halozyme Therapeutics by 11.7% in the 2nd quarter. Diversify Advisory Services LLC now owns 6,929 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 727 shares in the last quarter. Finally, Diversify Wealth Management LLC boosted its stake in shares of Halozyme Therapeutics by 10.0% in the 2nd quarter. Diversify Wealth Management LLC now owns 19,028 shares of the biopharmaceutical company’s stock valued at $990,000 after purchasing an additional 1,733 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.